> **Layer 1** · Medicine & Health Sciences · `H11-PRECISIONMED`

## Purpose
The **H11-PRECISIONMED** agent orchestrates multi-omics data integration (somatic and germline genomics, transcriptomics, proteomics, methylomics, and liquid biopsy ctDNA kinetics) with clinical phenotyping, pharmacogenomics, and digital health records. It synthesizes individualized N-of-1 therapeutic protocols, classifies molecular disease subtypes, predicts emergent resistance bypass pathways, matches clinical trials, and provides actionable decision support for Molecular Tumor Boards (MTBs) and personalized care teams.

---

## Technical Deep-Dive

### 1. Multi-Omic Heterogeneous Information Network (HIN) Fusion
H11-PRECISIONMED constructs a unified graph representation across biological layers:
- **Genomic Layer:** Somatic single-nucleotide variants (SNVs), insertions/deletions (indels), copy number alterations (CNAs: focal amplifications and deep deletions), and structural variants (oncogenic gene fusions such as *ALK*, *ROS1*, *RET*, *NTRK1/2/3*, *FGFR2/3*).
- **Epigenomic & Scar Signatures:** Homologous Recombination Deficiency (HRD) genomic scar scores (Loss of Heterozygosity [LOH], Telomeric Allelic Imbalance [TAI], and Large-Scale State Transitions [LST]), Microsatellite Instability (MSI-High vs MSS), Tumor Mutational Burden (TMB in mut/Mb), and CpG island methylator phenotypes (CIMP).
- **Transcriptomic & Microenvironment Deconvolution:** RNA-seq TPM quantification, pathway activity z-scores (e.g., MAPK/ERK, PI3K/AKT/mTOR, JAK/STAT, Wnt/$\beta$-catenin), and immune microenvironment cell-fraction estimation (CD8+ T-cell infiltration, Treg exhaustion markers, PD-L1/PD-1 expression).
- **Liquid Biopsy / Minimal Residual Disease (MRD):** Longitudinal circulating tumor DNA (ctDNA) variant allele frequency (VAF) kinetics and mean tumor fraction (MTF) tracking.

### 2. Actionability & Evidence Stratification
The agent applies standardized scoring frameworks aligned with the **ESCAT** (ESMO Scale for Clinical Actionability of molecular Targets) and **AMP/ASCO/CAP** guidelines:
- **Tier I (Standard of Care):** Biomarker-drug matches with prospective randomized clinical trial evidence or FDA-approved companion diagnostic status in the specific tumor type (e.g., *EGFR* L858R / exon 19 del with Osimertinib in NSCLC; *BRAF* V600E with Dabrafenib + Trametinib in melanoma).
- **Tier II (Investigational / Compelling Clinical Evidence):** Biomarkers with demonstrated activity in early-phase clinical trials or consensus clinical guideline recommendations.
- **Tier III (Hypothetical Clinical Benefit / Cross-Tumor Extrapolation):** Targetable alterations in non-indicated cancer types with biological rationale requiring functional pathway context (e.g., *BRAF* V600E in colorectal carcinoma necessitating concurrent EGFR blockade).
- **Tier IV (Preclinical / Synthetic Lethality):** Preclinical evidence of synthetic lethality or synergistic combination therapy (e.g., *ARID1A* loss conferring sensitivity to EZH2 inhibitors; *MTAP* deletion with MAT2A / PRMT5 inhibitors).

### 3. Synthetic Lethality & Multi-Criteria Decision Analysis (MCDA)
For therapeutic ranking, the agent executes a Bayesian Multi-Criteria Decision Analysis model balancing:
$$\text{Score}(T) = w_E \cdot \Phi_{\text{efficacy}}(T, \mathcal{M}) + w_{SL} \cdot \mathbb{I}_{SL}(T, \mathcal{G}) - w_{tox} \cdot \Psi_{\text{tox}}(T, \mathcal{P}_{PGx}, \mathcal{C}) + w_{trial} \cdot \Omega_{\text{trial}}(T)$$

Where:
- $\Phi_{\text{efficacy}}$ is the predicted pathway target inhibition potency and clinical response probability.
- $\mathbb{I}_{SL}$ represents synthetic lethality interaction bonuses (e.g., PARP inhibition in *BRCA1/2*, *PALB2*, or *RAD51C* deficient states).
- $\Psi_{\text{tox}}$ is the pharmacogenomic and organ-reserve toxicity penalty derived from CYP diplotypes, DPYD/TPMT status, eGFR, Child-Pugh class, and baseline ECOG performance score.
- $\Omega_{\text{trial}}$ is the matching eligibility score for active molecularly enriched clinical trials.

### 4. Clonal Architecture & Resistance Trajectory Modeling
The agent models evolutionary subclonal trees from variant allele frequencies adjusted for tumor purity and copy number. It identifies potential pre-existing subclonal resistance mutations (e.g., *EGFR* T790M / C797S, *KRAS* G12C switch-II bypass amplifications, *ESR1* Y537S mutations) and anticipates bypass pathway activation (e.g., *MET* amplification following EGFR-TKI monotherapy).

### 5. Dynamic Minimal Residual Disease (MRD) Tracking
Utilizing state-space Kalman filtering and Bayesian exponential decay models on longitudinal cell-free DNA time series:
$$\Delta \text{VAF}(t) = \text{VAF}_0 \cdot e^{-k_{\text{clearance}} \cdot t} + \epsilon(t)$$
The agent calculates the molecular clearance velocity ($k_{\text{clearance}}$), flags molecular progression ($v_{MRD} > 0$), and triggers preemptive therapy modification alerts weeks before radiographic RECIST 1.1 progression.

---

## Architecture

### Input Contract
| Field | Type | Description |
|---|---|---|
| `patient_id` | `str` | Unique patient identifier |
| `genomic_variants` | `List[GenomicVariant]` | Somatic and germline variants with VAF, depth, CNV log2 ratios, and zygosity |
| `biomarker_panel` | `BiomarkerPanel` | TMB (mut/Mb), MSI status, HRD score, PD-L1 TPS/CPS, hormone receptor status |
| `clinical_phenotype` | `ClinicalPhenotype` | Histological diagnosis, stage, ECOG PS, organ function labs (eGFR, LFTs), prior therapy lines |
| `pharmacogenomic_profile` | `PharmacogenomicProfile` | Diplotype determinations for *CYP2D6*, *CYP2C19*, *CYP2C9*, *DPYD*, *TPMT*, *UGT1A1* |
| `candidate_regimens` | `List[TherapeuticCandidate]` | Candidate targeted agents, immunotherapies, and combination regimens |
| `longitudinal_ctdna` | `Optional[List[ctDNASample]]` | Serial liquid biopsy time points for MRD clearance velocity calculation |

### Output Contract
| Field | Type | Description |
|---|---|---|
| `molecular_subtypes` | `List[str]` | Identified genomic/transcriptomic disease molecular subtype classes |
| `actionable_targets` | `List[ActionableTarget]` | Prioritized molecular targets with ESCAT/AMP tier rankings and pathways |
| `ranked_therapies` | `List[PersonalizedTherapyRecommendation]` | Ranked therapeutic regimens with composite score, predicted efficacy, toxicity penalty, and synthetic lethality rationale |
| `resistance_risks` | `List[ResistanceMechanism]` | Predicted resistance escape mechanisms, bypass pathways, and recommended surveillance |
| `mrd_protocol` | `MRDMonitoringProtocol` | Longitudinal ctDNA clearance velocity, molecular response status, and test intervals |
| `executive_summary` | `str` | Structured molecular tumor board briefing narrative |

### State Schema
- **Knowledge Graph Cache:** Actionability rule base indexed by gene, mutation, and tumor type.
- **CHIP Registry:** Filter dictionary for clonal hematopoiesis mutations (*DNMT3A*, *TET2*, *ASXL1*, *JAK2*, *PPM1D*) to prevent liquid biopsy misattribution.
- **Patient Longitudinal Ledger:** Serial ctDNA and treatment timeline state for dynamic response tracking.

---

## Dependencies

### Upstream (Input Feeds)
- `H11-GENETICA-MED`: Germline variant pathogenicity (ACMG classification) and polygenic risk scores.
- `H11-PHARMACOGENOMICA`: Enzyme metabolic phenotypes and baseline drug toxicity risks.
- `H11-PATHOLOGIA`: Histopathology grades, immunohistochemistry (IHC), and tissue cellularity.
- `H11-HEALTHINFORMATICA`: Longitudinal EHR/FHIR clinical history, lab panels, and prior treatment responses.
- `H11-IMMUNOTHERAPIA`: Immune infiltration indices, neoantigen load, and checkpoint markers.

### Downstream (Consuming Agents)
- `H11-ONCOLOGIA` / Clinical Oncology Subsystems: Execution of MTB-recommended therapeutic regimens.
- `H11-PALLIATIVA`: Toxicity monitoring, supportive care coordination, and symptom management.
- `H11-TELEMEDICINA`: Remote patient alert dispatching on ctDNA molecular progression triggers.

---

## Failure Modes & Mitigations

1. **Clonal Hematopoiesis of Indeterminate Potential (CHIP) Confounding:**
   - *Risk:* Peripheral blood cell-free DNA liquid biopsies misidentifying aging-related clonal hematopoiesis mutations (*DNMT3A*, *TET2*, *ASXL1*) as tumor-derived somatic variants.
   - *Mitigation:* Automated paired white blood cell (buffy coat) sequencing subtraction and heuristic CHIP gene filtering.

2. **Tissue Lineage Misextrapolation:**
   - *Risk:* Assuming an actionable mutation (e.g., *BRAF* V600E) confers identical monotherapy sensitivity in colorectal cancer as in melanoma, leading to ineffective care due to feedback EGFR activation.
   - *Mitigation:* Lineage-aware rule engines enforcing mandatory combination therapies (e.g., Encorafenib + Cetuximab) for specific histological contexts.

3. **Subclonal Target Over-Prioritization:**
   - *Risk:* Targeting a private subclonal mutation present in only a fraction of tumor cells (VAF << clonal trunk), resulting in rapid outgrowth of target-negative clones.
   - *Mitigation:* Clonal vs subclonal hierarchical weighting based on variant allele frequency adjusted for tumor purity.

4. **Multi-Target Metabolic Overload & Toxicity Synergy:**
   - *Risk:* Combining multiple targeted inhibitors (e.g., PI3K inhibitor + MEK inhibitor) inducing severe synergistic hepatotoxicity or colitis.
   - *Mitigation:* Pharmacogenomic hepatic/renal clearance modeling and dose-adjustment penalties integrated into MCDA scoring.

---

## Performance Characteristics
- **Computational Latency:** 
  - Standard biomarker actionability lookup: `< 350 ms`
  - Multi-omics pathway deconvolution and MCDA combinatorial ranking: `< 1.8 s`
  - Longitudinal ctDNA Kalman filter response kinetics: `< 120 ms`
- **Throughput:** `10,000+` comprehensive patient multi-omics profiles per hour on standard distributed compute nodes.

---

## Research References
1. **Mateo, J., et al. (2018).** "A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)." *Annals of Oncology*, 29(9), 1895-1902.
2. **Li, M. M., et al. (2017).** "Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer." *The Journal of Molecular Diagnostics*, 19(1), 4-23.
3. **Lord, C. J., & Ashworth, A. (2016).** "PARP inhibitors: Synthetic lethality in the clinic." *Science*, 355(6330), 1152-1158.
4. **Dawson, S. J., et al. (2013).** "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer." *New England Journal of Medicine*, 368(13), 1199-1209.
5. **Chakravarty, D., et al. (2017).** "OncoKB: A Precision Oncology Knowledge Base." *JCO Precision Oncology*, 1, 1-16.

---

## Implementation Notes
- Pure Python 3.10+ implementation with strongly typed dataclasses and asynchronous execution interfaces.
- Implements comprehensive mathematical scoring functions with explicit edge-case handling for missing biomarker panels and multi-organ impairment.
